Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Prostate Cancer Diagnosis and Staging

  • Author: Lanna Cheuck, DO; Chief Editor: Edward David Kim, MD, FACS  more...
 
Updated: Jun 21, 2016
 

Practice Essentials

Prostate cancer is the most common noncutaneous cancer among males, making the diagnosis and staging of this cancer of great medical and public interest. Although prostate cancer can be slow growing, the disease nonetheless accounts for almost 10% of cancer-related deaths in males, with thousands of men dying of prostate cancer each year (see the image below).

Estimated incidence of and mortality from prostate Estimated incidence of and mortality from prostate cancer. Courtesy of the American Cancer Society.

Screening controversies

Digital rectal examination (DRE) and PSA evaluation are the two components necessary for a modern screening prostate cancer program. However, there is controversy regarding screening.

Advocates of screening for prostate cancer believe that early detection is crucial to finding organ-confined disease and to reducing the likelihood of mortality. When symptoms develop or when DRE results become positive, most cases have already advanced beyond organ-confined disease. However, those who do not advocate screening worry that screening will detect cancers that are not biologically significant (ie, in patients who will die with prostate cancer rather than from it).

The American Cancer Society (ACS),[1] the American Urological Association (AUA),[2] and the National Comprehensive Cancer Network (NCCN),[3] have issued guidelines that differ on specific points but agree on the value of prostate cancer screening in selected populations, for patients who agree to screening after a discussion of the risks and benefits. In contrast, the U.S. Preventive Services Task Force (USPSTF) recommends against PSA-based prostate cancer screening,[4] and the European Society for Medical Oncology (ESMO) recommends against population-based PSA screening for prostate cancer on the grounds that it reduces prostate cancer mortality at the expense of overdiagnosis and overtreatment.[5]

Signs and symptoms

With the advent of PSA screening, patients report the following local symptoms:

  • No symptoms (47%)
  • Urinary frequency (38%)
  • Urinary urgency (10%)
  • Decreased urine stream (23%)
  • Hematuria (1.4%)

Metastatic symptoms of prostate cancer include the following:

  • Weight loss and loss of appetite
  • Bone pain, with or without pathologic fracture
  • Lower extremity pain and edema
  • Uremic symptoms

Diagnosis

Laboratory studies

  • PSA screening: Controversy exists regarding PSA level cutoffs and reference ranges
  • DRE: Serial examinations are best; clues to the patient’s condition in conjunction with PSA levels include presence of a nodule, as well as asymmetry, texture difference(s), and bogginess of the prostate, seminal vesicles, and adjacent organs
  • Biopsy and histologic examination: These aid in the diagnosis and help to determine the Gleason score; a biopsy can also help differentiate a cyst or calculus from cancer foci

Imaging studies

  • Computed tomography (CT) scanning: To assess extension into the bladder and lymph nodes for staging the cancer or for considering pretreatment lymph node sampling
  • Endorectal magnetic resonance imaging (MRI): To localize cancer within the prostate and seminal vesicles; to help in local staging
  • Bone scanning: To evaluate bone metastasis
  • MRI: To determine the etiology of questionable lesions found on bone scans
  • Transrectal ultrasonography: To examine the prostate for hypoechoic areas, which are commonly associated with cancers but are not specific enough for diagnostic purposes

Men with PSA levels above 10 ng/mL, high-grade histology (Gleason score of ≥7), or physical findings suggesting stage T3 disease should probably undergo a staging CT scan and bone scan. Neither CT scanning nor MRI can be used to determine if lymph nodes are reactive or contain malignant deposits, unless the nodes are significantly enlarged and a percutaneous biopsy can be performed.

TNM staging and grouping of prostate cancer

Tumor[6]

  • T – Primary tumor
  • TX – Primary tumor cannot be assessed
  • T0 – No evidence of primary tumor
  • T1 – Clinically inapparent tumor not palpable or visible by imaging
  • T1a – Tumor incidental histologic finding in 5% or less of tissue resected
  • T1b – Tumor incidental histologic finding in greater than 5% of tissue resected
  • T1c – Tumor identified by needle biopsy (due to elevated prostate-specific antigen [PSA] level); tumors found in 1 or both lobes by needle biopsy but not palpable or reliably visible by imaging
  • T2 – Tumor confined within prostate
  • T2a – Tumor involving less than half a lobe
  • T2b – Tumor involving 1 lobe or less
  • T2c – Tumor involving both lobes
  • T3 – Tumor extending through the prostatic capsule; no invasion into the prostatic apex or into, but not beyond, the prostatic capsule
  • T3a – Extracapsular extension (unilateral or bilateral)
  • T3b – Tumor invading seminal vesicle(s)
  • T4 – Tumor fixed or invading adjacent structures other than seminal vesicles (eg, bladder neck, external sphincter, rectum, levator muscles, pelvic wall)
  • NX – Regional lymph nodes (cannot be assessed)
  • N0 – No regional lymph node metastasis
  • N1 – Metastasis in regional lymph node or nodes

Regional lymph nodes[6]

Regional lymph nodes are assessed via surgical removal or through biopsy of the pelvic lymph nodes, including the obturator chain. The surgical boundaries include the bifurcation of the common iliac, the obturator nerve, and the node of Cloquet.

Distant metastasis[6]

  • PM1c – More than 1 site of metastasis present
  • MX – Distant metastasis cannot be assessed
  • M0 – No distant metastasis
  • M1 – Distant metastasis
  • M1a – Nonregional lymph node(s)
  • M1b – Bone(s)
  • M1c – Other site(s)

Stage groupings

The TNM system for grouping prostate cancer is based on the following 5 key pieces of information[7] :

  • The extent of the primary tumor (T category)
  • Whether the cancer has spread to nearby lymph nodes (N category)
  • The absence or presence of distant metastasis (M category)
  • The PSA level at the time of diagnosis
  • The Gleason score, based on prostate biopsy (or surgery)

Stage I - Cancer found in the prostate only

  • T1, N0, M0, Gleason score 6 or less, PSA less than 10 or
  • T2a, N0, M0, Gleason score 6 or less, PSA less than 10

Stage II (IIa and IIb) - Cancer is more advanced than stage I, but has not spread outside the prostate

Stage IIa - One of the following applies:

  • T1, N0, M0, Gleason score of 7, PSA less than 20 or
  • T1, N0, M0, Gleason score of 6 or less, PSA at least 10 but less than 20 or
  • T2a or T2b, N0, M0, Gleason score of 7 or less, PSA less than 20

Stage IIb - One of the following applies:

  • T2c, N0, M0, any Gleason score, any PSA or
  • T1 or T2, N0, M0, any Gleason score, PSA of 20 or more or
  • T1 or T2, N0, M0, Gleason score of 8 or higher, any PSA

Stage III - Cancer has spread outside the prostate and may have invaded the seminal vesicles

  • T3, N0, M0, any Gleason score, any PSA

Stage IV - Cancer has spread outside the prostate, into surrounding pelvic organs, into lymph nodes, or as distant metastasis outside the pelvis

  • T4, N0, M0, any Gleason score, any PSA or
  • Any T, N1, M0, any Gleason score, any PSA or
  • Any T, any N, M1, any Gleason score, any PSA
Next

Overview

Prostate cancer is the most common noncutaneous cancer among males, making the diagnosis and staging of this cancer of great medical and public interest. Although prostate cancer can be slow growing, the disease nonetheless accounts for almost 10% of cancer-related deaths in males, with thousands of men dying from prostate cancer each year.

With the development of prostate-specific antigen (PSA) screening, however, prostate cancer is being diagnosed earlier in the disease course than it was prior to PSA examination.

Currently, most cases of prostate cancer are found because of abnormalities in a screening PSA level or findings on digital rectal examinatiDRE rather than because of symptoms (see Prostate-Specific Antigen). However, prostate cancer can be an incidental pathologic finding when tissue is removed during transurethral resection to manage obstructive prostatic symptoms (see Benign Prostatic Hypertrophy).

The American Cancer Society (ACS) estimated that 240,890 new cases of prostate cancer were diagnosed in the United States in 2011 and that 33,720 men died of the disease in that year. (See the chart below.) Comparable ACS estimates for 2016 are 180,890 new cases and 26,120 deaths.[8]

Estimated incidence of and mortality from prostate Estimated incidence of and mortality from prostate cancer. Courtesy of the American Cancer Society.

For more information, see the following:

Age- and race-related demographics

Prostate cancer is rarely diagnosed in men younger than 40 years, and it is uncommon in men younger than 50 years.

Prevalence rates of prostate cancer remain significantly higher in African-American men than in white men, while the prevalence in Hispanic men is similar to that of white men. Hispanic men and African-American men tend to present with more advanced disease, a situation that is most likely related to external (eg, income, education, insurance status) and cultural factors. In addition, African-American men generally have higher levels of testosterone, which may contribute to the higher incidence of carcinoma in that population.[9, 10]

Mutations that appear specific to, or more common in, African-American patients have been identified in aggressive prostate tumors. Further research will be needed to determine whether these mutations factor into the racial differences in incidence and clinical outcome that are seen in prostate cancer.[11]

Differentials

Differential diagnoses of prostate cancer include the following:

  • Benign prostatic hypertrophy
  • Calculi
  • Prostatic cysts
  • Prostatic tuberculosis
  • Prostatitis

Patient education

Because of the advent of PSA screening, a greater number of men now require education about prostate cancer, including the risk of progression and how the disease is diagnosed, staged, and treated. A study by Hall et al found that 80% of primary care physicians discussed PSA screening with their male patients, with 64.1% encouraging the screening.[12]

For patient education information, see the Men's Health Center and the Cancer Center, as well as Prostate Cancer.

Previous
Next

Relevant Anatomy

The prostate lies below the bladder and encompasses the prostatic urethra. It is surrounded by a capsule and is separated from the rectum by a layer of fascia termed the Denonvilliers aponeurosis. The position of the prostate in the male genitourinary tract is shown in the image below.

Relevant anatomy of the male pelvis and genitourin Relevant anatomy of the male pelvis and genitourinary tract.

The blood supply to the base of the bladder and prostate is from the inferior vesical, which is derived from the internal iliac. The capsular branches of the inferior vesical artery help to identify the pelvic plexus arising from the S2-S4 and T10-T12 nerve roots.

The neurovascular bundle lies on either side of the prostate on the rectum. It is derived from the pelvic plexus and is important for erectile function.

Previous
Next

Characteristics of Prostate Cancer

Ninety-five percent of prostate cancers are adenocarcinomas. In approximately 4% of men with prostate cancer, the neoplasm has transitional cell morphology and is thought to arise from the urothelial lining of the prostatic urethra.

In rare cases, the tumor has a neuroendocrine morphology; in such instances the neoplasm is believed to have arisen from the neuroendocrine stem cells that are normally present in the prostate or from aberrant differentiation programs during cell transformation.

Seventy percent of prostate cancers arise in the peripheral zone, 15-20% arise in the central zone, and 10-15% arise in the transition zone.

Previous
Next

Screening Indications and Controversies

Digital rectal examination (DRE) and prostate-specific antigen (PSA) measurement are the two components necessary for a modern screening program.

The indications for screening are controversial. Advocates of screening believe that early detection is crucial to finding organ-confined disease and to reducing the likelihood of mortality. When symptoms develop or when DRE results become positive, most cases have already advanced beyond organ-confined disease. Those who do not advocate screening worry that screening will detect cancers that are not biologically significant (ie, in patients who will die with prostate cancer rather than from it), and subject patients to the risks of unnecessary intervention.

The American Cancer Society (ACS) recommends that asymptomatic men with at least a 10-year life expectancy should be given an opportunity to make an informed decision with their health care provider after receiving information on the uncertainties, risks, and benefits of screening PSA evaluation. The recommended age at which men should receive this information varies by prostate cancer risk, as follows[1] :

  • Age 50 for those at average risk of developing prostate cancer
  • Age 45 for those at high risk, including African Americans and men with a first-degree relative (father, brother, son) diagnosed with prostate cancer before age 65
  • Age 40 for those at higher risk (more than one first-degree relative diagnosed with prostate cancer at an early age)

Men who decide to be screened should be tested with a PSA test. A DRE may also be done as a part of screening. If screening does not detect cancer, the time between subsequent screenings depends on the PSA results, as follows[1] :

  • <2.5 ng/ml – Retesting may be done every 2 years
  • ≥2.5 ng/ml – Retesting should be done annually

The National Comprehensive Cancer Network (NCCN) notes the importance of identifying aggressive prostate cancer while avoiding the detection of indolent disease. For men 45-75 years old, the NCCN recommends a discussion of screening risks and benefits, followed by a baseline PSA and consideration of a DRE, especially in men with an elevated PSA level.[3]

The NCCN recommends basing repeat testing intervals on PSA and DRE findings, as follows:

  • PSA <1 ng/mL, DRE normal (if done) – 2-4 years
  • PSA 1-3 ng/mL, DR normal (if done) – 1-2 years

For patients with PSA levels above 3 ng/mL or very suspicious DRE results, the NCCN recommends repeat PSA, DRE, and workup for benign disease. Considerations regarding transrectal ultrasound (TRUS)–guided biopsy should take into account the correlation between PSA levels and the likelihood of finding prostate cancer on biopsy, which is as follows:

  • PSA ≤4 ng/mL – 15%
  • PSA 4-10 ng/mL – 30-35%
  • PSA >10 ng/mL - >67%

American Urological Association (AUA) recommend against routine screening for the following groups[2] :

  • Any man with a life expectancy less than 10-15 years
  • Men under 40 years
  • Men between ages 40 to 54 years at average risk
  • Men over age 70

For men 55 to 69 years of age, the AUA advises that the decision to undergo PSA screening involves weighing the benefits and risks. The guidelines strongly recommend the following[2] :

  • Shared decision-making for men age 55-69 years who are considering PSA screening, and proceeding based on patients’ values and preferences
  • A routine screening interval of 2 years or more in those men who have participated in shared decision-making and decided on screening.

Contrasting study data

Data from a Canadian study showed that from 1989-1996, the mortality rate was lower in a PSA-screened cohort than in a control group. Research from Tyrol, Austria, also indicated that screening can aid in reducing disease-specific mortality.

These beneficial effects are likely due to the fact that treatment, rather than observation, may enhance disease-specific survival. This was indicated in a Scandinavian study, which reported that radical prostatectomy was associated with significantly reduced disease-specific mortality, compared with watchful waiting. (No difference in overall survival was noted.)[13]

However, a US study, the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, compared patients who received annual screening (the study offered PSA tests for 6 years and DREs for 4 years) with patients who did not undergo yearly testing and found no screening-related improvement in mortality.[14] Conversely, the European Randomized Study of Screening for Prostate Cancer (ERSPC) did show a decreased mortality in the trial's PSA-screened group; however, this multicenter study was flawed.[15]

Similar to the American study, a randomized trial comparing Swedish men allocated to screening every third year with those who received no screening showed no difference in prostate cancer–specific survival.[16] The issue remains unresolved.

US data have shown a decrease of 1% per year since 1990 in the prostate-cancer mortality rate, which coincides with the advent of PSA screening. Other theories have been proposed to account for the decrease; these include changing treatment practices and artifacts in mortality rates secondary to the changing incidence of prostate cancer.

Discontinuation of screening

In a 2010 study, Tang et al concluded that in the 75- to 80-year age group, discontinuation of PSA screening may be safe in African-American men with an initial PSA measurement of less than 6.0 ng/mL and in Caucasian men with an initial PSA measurement of less than 3.0 ng/mL. The investigators found that men in these groups are unlikely to develop high-risk prostate cancer or to die from prostate cancer.[17]

The NCCN advises that, although very few men over the age of 75 benefit from PSA testing, a clinically significant number may develop aggressive cancers that pose significant risk if they are not detected before they produce symptoms. For that reason, testing may be considered in select patients who are very healthy and have little or no comorbidity, but clinicians may consider raising the threshold for biopsy to a PSA level of >4 ng/mL.[3]

Recommendations against screening

In 2012, the US Preventive Services Task Force (USPSTF) recommended against PSA-based screening for prostate cancer.[4] After reviewing screening trials (including the PLCO Cancer Screening Trial and the ERSPC), the USPSTF concluded that PSA-based screening results in little or no decrease in prostate cancer–specific mortality and that the benefits of such screening do not outweigh the potential pitfalls of resulting evaluation and treatment (eg, surgery-related erectile dysfunction and urinary incontinence).[18] An update of the USPSTF recommendation is currently in progress.

Similarly, in 2015, the European Society for Medical Oncology (ESMO) recommended against population-based PSA screening for prostate cancer, on the grounds that it reduces prostate cancer mortality at the expense of overdiagnosis and overtreatment. The ESMO also recommended against testing for prostate cancer in asymptomatic men over the age of 70 years,[5]

Previous
Next

Prostate Cancer Symptoms

Local symptoms

In the pre-PSA era, patients with prostate cancer commonly presented with local symptoms. Urinary retention developed in 20-25% of these patients, back or leg pain developed in 20-40%, and hematuria developed in 10-15%. Currently, with PSA screening, 47% of cases are diagnosed in asymptomatic patients. In symptomatic patients, te most common complaints are urinary frequency (38%), decreased urine stream (23%), urinary urgency (10%), and hematuria (1.4%). However, none of these symptoms is unique to prostate cancer; each can arise from various other ailments.

Metastatic symptoms

Metastatic symptoms include weight loss and loss of appetite; bone pain, with or without pathologic fracture (because prostate cancer, when metastatic, has a strong predilection for bone); and lower extremity pain and edema due to obstruction of venous and lymphatic tributaries by nodal metastasis. Uremic symptoms can occur from ureteral obstruction caused by local prostate growth or retroperitoneal adenopathy secondary to nodal metastasis.

Previous
Next

Prostate-Specific Antigen Screening

Elevated PSA level

PSA is a single-chain glycoprotein that has chymotrypsinlike properties. The upper limit of normal for PSA is 4ng/mL. Some advocate age-related cutoffs, such as 2.5ng/mL for the fifth decade of life, 3.5ng/mL for the sixth decade of life, and 4.5ng/mL for the seventh decade of life. Others advocate race-specific reference ranges. Using data from screening studies, some have advocated upper limits of normal of 2.5ng/mL instead of 4ng/mL.

If the physician believes that an elevated PSA level may be due to infection, 4-6 weeks of antibiotics are provided, and then the PSA level is rechecked.

PSA velocity

PSA velocity is an important concept. A PSA velocity of lower than 0.75ng/mL/y has traditionally been used to prompt a prostate biopsy. However, evidence suggests in men younger than 50 years, a PSA velocity of 0.6 ng/mL/y may be more appropriate.

Percentage of free PSA

The measurement of bound and free PSA can help to differentiate mildly elevated PSA levels caused by cancer from elevated levels resulting from benign prostatic hyperplasia. The lower the ratio of free-to-total PSA, the higher the likelihood of cancer. (Free PSA is reported as a percentage.) For example, among men with greater than 25% free PSA, only 8% are found to have cancer at prostate biopsy.

In contrast, more than half of men with less than 10% free PSA are found to have cancer at biopsy. While cutoffs may be used, the percentage of free PSA is usually employed as an additional factor in making an informed recommendation for or against biopsy. Generally, these percentages are useful in patients who have a PSA level in the range of 4-10ng/mL.

This information is most useful in men with very large glands or in whom 1 biopsy result has already been negative. In healthy men with a PSA level of 4-10ng/mL, many recommend biopsy without the additional free-PSA test or consider a trial of antibiotic therapy for 4-6 weeks before repeating the PSA test. (If antibiotic therapy quickly lowers the PSA level to within the reference range, the cause of the prior elevation is less likely to be prostate cancer, and the PSA test should be repeated within a few months.)

Prostate Health Index testing

The Prostate Health Index (PHI) test is a diagnostic blood test that combines free and total PSA and the (-2) pro-PSA isoform (p2PSA). The PHI test is intended to reduce the number of unnecessary prostate biopsies in PSA-tested men. In prospective multicenter studies, the PHI test has outperformed free and total PSA for detection of prostate cancer and has improved prediction of clinically significant prostate cancer in men with a PSA of 2 or 4 ng/mL to 10 ng/mL.[19]

Previous
Next

Digital Rectal Examination

DREs are examiner dependent, and serial examinations are best. Various factors are considered when a DRE is performed. A nodule is important, but findings such as asymmetry, difference in texture, and bogginess are important clues to the patient's condition and should be considered in conjunction with the PSA level. Change in texture over time can offer important clues about the need for intervention.

Pay careful attention to the prostate’s consistency, along with the seminal vesicles and adjacent organs. Such observation can be help to detect the disease’s spread to other structures, the results of which can be as follows:

  • Overdistention of the bladder due to outlet obstruction
  • Lower extremity lymphedema
  • Supraclavicular adenopathy
  • Lower extremity deep venous thrombosis
  • Cancer cachexia
  • Neurologic findings secondary to cord compression - Other subtle neurologic findings, such as paresthesias or wasting, are uncommon

Cysts and stones cannot be accurately differentiated from cancer based on DRE findings alone; therefore, maintain a high index of suspicion if the DRE results are abnormal.

If cancer is detected, the DRE findings form the basis of clinical staging of the primary tumor using the TNM staging system.

In most patients who are diagnosed with prostate cancer, however, the DRE results are normal and the PSA readings are abnormal.

Previous
Next

Biopsy Studies

Physical examination findings alone cannot reliably differentiate a cyst or calculus from cancer foci. Therefore, a biopsy is warranted in these circumstances, to aid in the diagnosis and to determine the Gleason score.

Before the biopsy, antibiotics are administered and an enema is often provided, with a short course of antibiotics administered after the biopsy as well. Coagulation tests are not routinely performed, but patients are instructed to stop aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) 10 days prior to the biopsy. Many, but not all, physicians use lidocaine prior to the biopsy.

The number of biopsy specimens that should be obtained is debated. Sextant- versus 12- versus 18-core biopsy protocols are published in the literature. The 12- or 18-core protocols yield more specimens from the lateral regions and usually sample the transition zone. Several studies have demonstrated an increase in the cancer detection rate, but others have not. The NCCN recommends extended-pattern biopsy with six sextant cores and six cores from the lateral peripheral zone, along with lesion-directed sampling of palpable nodules and sites corresponding to suspicious images.[3]

In men with a negative biopsy result, epigenetic profiling with the ConfirmMDx assay (MDxHealth, Irvine, CA) may help to distinguish patients who have a true negative biopsy from those at risk for occult cancer. ConfirmMDx is a commercially available assay that assesses methylation markers of prostate cancer (GSTP1, APC, and RASSF1) to distinguish histologically benign biopsy cores from patients diagnosed with no cancer, low-volume cancer (Gleason score 6), or higher-volume cancer (Gleason score 7). The assay has a negative predictive value of 90%, but a positive predictive value of only 28%.[20]

PCA3 is a prostate-specific, non-coding messenger RNA biomarker that is detectable in urine sediments obtained after three strokes of prostatic massage during DRE. A urine test for PCA3 (Progensa PCA3) is commercially available. Currently, the main indication for PCA3 testing is to help determine whether repeat biopsy is needed after an initially negative biopsy. A negative result, considered together with clinical and other laboratory information, would argue against repeat biopsy.[19]

In patients with a persistently elevated PSA level in the face of negative biopsy results, the literature supports repeating the biopsy once or twice. Among cancer cases, 31% were detected on repeat biopsy and 39% were detected if the PSA value was greater than 20ng/mL. If all of the biopsy results are negative, a repeat round of biopsies has been suggested when the PSA increases by 25% from the level at which the last biopsies were performed.

According to European guidelines, indications for repeat biopsy after a previously negative biopsy are as follows[19] :

• Rising and/or persistently elevated PSA

• Suspicious findings on DRE (5-30% cancer risk)

• Atypical small acinar proliferation (ie, atypical glands suspicious for cancer; 40% risk)

• High-grade prostatic intraepithelial neoplasia (HGPIN) at ≥3 biopsy sites (~30% risk)

• A few atypical glands immediately adjacent to HGPIN (~50% risk)

The guidelines recommend that repeat biopsies after negative biopsies be performed with MRI targeting.

Further workup depends on the clinical staging. A higher clinical stage of cancer determined by DRE findings, PSA level, and Gleason score (as determined by biopsy) correlates with an increased risk of extraprostatic spread, and these tests are considered key factors in determining the staging workup and predicting patient prognosis.

Bul et al studied the factors predicting reclassification from low-risk to higher-risk prostate cancer in men undergoing active surveillance and found a significant association between an increase in risk classification and the number of initial positive biopsy cores obtained. However, patient age, clinical stage, total number of biopsy cores, and PSA did not significantly influence the outcome. (Although a PSA doubling time of under 3y also had a significant link to reclassification to higher risk.[21] )

Previous
Next

Histologic Findings

Gleason score

The most commonly used system for classifying the histologic characteristics of prostate cancer is the Gleason scoring system, which uses the glandular architecture within the tumor.

The predominant pattern and the second-most common pattern (seen in the image below) are each given a grade of between 1 and 5. The Gleason score is the sum of these 2 grades. Scoring based on the 2 most common patterns is an attempt to factor in the considerable heterogeneity within cases of prostate cancer. In addition, this scoring method was found to be superior for predicting disease outcomes compared with using the individual grades alone.

Histologic scoring system (the Gleason scoring sys Histologic scoring system (the Gleason scoring system) showing the 2 most common patterns seen on biopsy specimens in prostate cancer.

Grades are based on the extent to which the epithelium assumes a normal glandular structure. A grade of 1 indicates a near-normal pattern, and grade 5 indicates the absence of any glandular pattern (less malignant to more malignant). This scheme of grading histologic features greatly depends on the skill and experience of the pathologist and is subject to some degree of individual variation.

Gleason scores range as follows:

  • Score of 2-4 - Considered low grade or well differentiated
  • Score of 5-7 - Considered moderate grade or moderately differentiated
  • Score of 8-10 - Considered high grade or poorly differentiated

Although the change in glandular architecture represented by the Gleason score is currently the most widely used and correlative histologic parameter, it is not the only histologic change that can be observed in prostate cancers. Indeed, notable changes in cell and nuclear morphology, neuroendocrine differentiation, and vascularity can be observed and may have great prognostic significance.

Perineural invasion

Perineural invasion is an indicator of invasiveness and is considered in terms of which side should possibly undergo a nerve-sparing procedure, as well as whether a patient might benefit more from high- or low-risk brachytherapy.

Prostatic intraepithelial neoplasia

Prostatic intraepithelial neoplasia (PIN) represents the putative precancerous end of the morphologic continuum of cellular proliferations within prostatic ducts, ductules, and acini.

Two grades of PIN are identified. Low-grade PIN is mild dysplasia. High-grade PIN encompasses moderate and severe dysplasia. High-grade PIN is considered by most to be a precursor of invasive carcinoma. Men with high-grade PIN alone can be started on finasteride and monitored closely.

The continuum that culminates in high-grade PIN and early invasive cancer is characterized by basal cell layer or basement membrane disruption, progressive loss of secretory differentiation markers, increasing nuclear and nucleolar abnormalities, increasing proliferative potential, and increasing variation in deoxyribonucleic acid (DNA) content (aneuploidy).

Clinical studies suggest that PIN predates a carcinoma by 10 or more years.[22] The clinical importance of recognizing PIN is based on its strong association with carcinoma. Studies claim that men with high-grade PIN in a prostate biopsy specimen have a 35-50% chance of being diagnosed with prostate cancer after a subsequent biopsy.[23] Atypical small acinar proliferation (ASAP) has also been associated with higher cancer detection rates.

The identification of PIN in prostate biopsy specimens warrants further searching for concurrent invasive carcinoma. In most men, this means repeat biopsies if the PSA level changes significantly. The same may also be true for ASAP findings after biopsy.

Evaluation of findings

Men with PSA levels below 10ng/mL and low- or moderate-grade histology (Gleason score < 7) with no findings or minimal findings on physical examination may proceed to surgery or brachytherapy without further studies.

Previous
Next

CT Scanning, MRI, and Bone Scanning

Men with PSA levels above 10ng/mL, high-grade histology (Gleason score of 7 or higher), or physical findings that suggest stage T3 disease should probably undergo a staging computed tomography (CT) scan and bone scan. CT scanning is the one modality with evidence-based guidelines. The CT scan can be used to evaluate extension into the bladder and lymph nodes to help stage the patient's cancer or to consider lymph node sampling prior to treatment.

Conventional endorectal magnetic resonance imaging (MRI) is helpful for localizing cancer within the prostate and seminal vesicles and for local staging. Dynamic, contrast-enhanced MRI and MR spectroscopic imaging are complementary in local staging, but their use is currently limited to a research setting.

Diffusion-weighted MRI appears to improve detection of transition-zone prostate cancer. In a retrospective study of 156 prostate cancer patients before they underwent radical prostatectomy, the addition of diffusion-weighted endorectal magnetic resonance imaging (MRI) to T2-weighted imaging improved not only the detection of transition zone prostate cancer but also the evaluation of tumor aggressiveness.[24] At the (individual) patient and sextant (localization) levels, there was improvement in the areas under the receiver operating characteristic curves. There was also an inverse correlation between tumor apparent diffusion coefficients and tumor Gleason scores in the transition zone.[24]

Guidelines from the National Comprehensive Cancer Network (NCCN)[25] and the European Association of Urology[19] note that evidence supports the use of multi-parametric MRI (mpMRI)—that is, the combination of T2-weighted images with diffusion-weighted imaging, dynamic contrast enhanced imaging, or H1-spectroscopy—in prostate cancer staging. The advantages of mpMRI include the following[25] :

  • Detection of large and poorly differentiated tumors (ie, Gleason score ≥7)
  • T staging: Detection of extracapsular extension, with high negative predictive values in low-risk men
  • N staging: MpMRI is equivalent to CT scan
  • M staging: MpMRI outperforms bone scan and targeted x-rays for M staging, with 98-100% sensitivity and specificity

Although MRI is superior to bone scanning in evaluating bone metastasis, it is impractical for routine total-body surveys. Instead, it is used to determine the etiology of questionable lesions found on bone scans. Bone-scan examples are seen below.

Anterior and posterior bone scans of a patient wit Anterior and posterior bone scans of a patient with prostate cancer, with metastasis to the 12th rib and thoracic spine represented by the increased uptake of isotope.

Neither CT scanning nor MRI can be used to determine if lymph nodes are reactive or contain malignant deposits, unless the nodes are significantly enlarged and a percutaneous biopsy can be performed.

Despite the wealth of literature regarding the lack of use that imaging studies have in men with low-risk disease, more than one third of patients with low-risk prostate cancer in a SEER (Surveillance, Epidemiology, and End Results program)-Medicare analysis underwent imaging studies.[26]

Previous
Next

Other Imaging Modalities

PET scanning

There is increasing interest in using metabolic activity to detect cancer foci. Positron emission tomography (PET) scanning uses glucose analogue 18 F-fluorodeoxyglucose (18 F-FDG) to detect cancer, but studies thus far have been disappointing for prostate cancer detection.

C-choline PET scanning fused with CT imaging shows more promise but is not yet the standard of care.

Fluciclovine F 18 (Axumin) was approved in May 2016 for PET imaging in men with suspected prostate cancer recurrence. Approval was based on a comparative trial with 11C-choline. Sensitivities for 11C-choline and fluciclovine F 18 were 32% vs 37%, specificities 40% vs 67%, accuracies 32% vs 38%, and positive predictive values (PPVs) 90% vs 97%.[37] A second trial observed the diagnostic performance of fluciclovine PET/CT in recurrent prostate cancer was superior to that of CT and fluciclovine PET/CT provided better delineation of prostatic from extraprostatic recurrence.[38]

ProstaScint scanning

Likewise, there is renewed interest in ProstaScint scans fused with MRI or CT images. ProstaScint scanning involves the use of a murine monoclonal antibody that reacts with prostate-specific membrane antigen to identify cancer in the prostate and in metastatic deposits.

TRUS

Transrectal ultrasonography (TRUS) is used to examine the prostate for hypoechoic areas, which are commonly associated with cancers but are not specific enough for diagnostic purposes. An example of a hypoechoic lesion is seen below.

Transrectal sonogram of the prostate showing a hyp Transrectal sonogram of the prostate showing a hypoechoic lesion in the peripheral zone of the gland that is suggestive of cancer.

MRI-TRUS fusion

The over-detection of clinically insignificant or low-risk cancer of the prostate by systemic or standard 12-core TRUS biopsy technique has spurred the development of a more targeted approach to obtaining prostate biopsy. MRI-TRUS fusion biopsy uses software that superimposes images obtained from MRI onto real-time ultrasound for a targeted biopsy of the prostate. This approach has shown potential in improving detection of clinically significant prostate cancer when compared with systemic prostate biopsy.

In a phase III trial that included 105 patients, MRI-TRUS fusion–guided biopsy detected prostate cancer that was missed by standard 12-core biopsy in 14.3% of cases, of which 86.7% were clinically significant, and upgraded 23.5% of cancers deemed clinically insignificant on 12-core biopsy to clinically significant prostate cancer.[27]

A prospective study in 1003 patients demonstrated the superior accuracy of MRI-TRUS fusion targeted biopsy compared with standard systemic biopsy for detection of high-risk prostate disease (Gleason score ≥4+3).[28] Targeted biopsy diagnosed 30% more high-risk cancers than did standard biopsy (173 vs 122 cases, P <0.001) and 17% fewer low-risk cancers (213 vs 258 cases, P <0.001) (28). When standard and targeted biopsy were combined, an additional 103 cases were diagnosed, mostly of low-risk disease.[28] d

In a retrospective review by Sankineni et al of 33 patients with sub-capsular lesions evaluated by standard 12-core TRUS-guided biopsy and MRI-TRUS fusion-guided biopsy, 24 patients were found to have cancerous sub-capsular lesions[29] . Of those 24 cases, 19 were confirmed by fusion-targeted biopsy and standard TRUS-guided biopsy; however, five lesions were identified only by fusion-targeted biopsy.[29] The improved detection of sub-capsular lesions shown in this study further supports the role of fusion-targeted biopsy, as sub-capsular lesions are commonly aggressive tumors.[29]

One disadvantage of MRI-TRUS fusion-guided biopsy is the cost of software.[30] In a retrospective study, Alberts et al used the Rotterdam Prostate Cancer Risk Calculator (RPCRC) to evaluate its potential in avoiding unnecessary MRI imaging.[31] In 122 patients who underwent multiparametric MRI (mpMRI) with subsequent MRI-TRUS fusion-guided biopsy after initially having negative TRUS, RPCRC could have avoided 62 (51%) mpMRI’s after a negative TRUS-guided random biopsy performed because of prostate-specific antigen level and/or digital rectal examination findings.[31]

With the growing acceptance of active surveillance protocols for men with localized disease, more patients are undergoing active surveillance for management of their prostate cancer.  MRI-TRUS fusion-guided biopsy has the potential to add diagnostic value in identifying candidates for active surveillance.    

Hu et al. used targeted biopsy to determine whether Epstein criteria (Gleason score 6 or less, 2 or fewer cores positive, and 50% or less of any core) were sufficient for identifying candidates for active surveillance.[32] Targeted biopsy with mpMRI-TRUS fusion was performed in 113 patients undergoing active surveillance.[32] The likelihood of reclassification in lesions with grades 4 or 5 on mpMRI based on Standards of Reporting for MRI targeted biopsy studies (START) was 45% and 100%, respectively.[32] These rates of reclassification show the potential utility of targeted fusion biopsy for identifying candidates for active surveillance protocols. 

Previous
Next

Staging of Prostate Cancer

The 2002 tumor node metastases [TNM] staging system for prostate cancer is as follows[6] :

  • T - Primary tumor
  • TX - Primary tumor cannot be assessed
  • T0 - No evidence of primary tumor
  • T1 - Clinically inapparent tumor not palpable or visible by imaging
  • T1a - Tumor incidental histologic finding in less than or equal to 5% of tissue resected
  • T1b - Tumor incidental histologic finding in greater than 5% of tissue resected
  • T1c - Tumor identified by needle biopsy (because of elevated PSA level); tumors found in 1 or both lobes by needle biopsy but not palpable or reliably visible by imaging
  • T2 - Tumor confined within prostate
  • T2a - Tumor involving less than half a lobe
  • T2b - Tumor involving less than or equal to 1 lobe
  • T2c - Tumor involving both lobes
  • T3 - Tumor extending through the prostatic capsule; no invasion into the prostatic apex or into, but not beyond, the prostatic capsule
  • T3a - Extracapsular extension (unilateral or bilateral)
  • T3b - Tumor invading seminal vesicle(s)
  • T4 - Tumor fixed or invading adjacent structures other than seminal vesicles (eg, bladder neck, external sphincter, rectum, levator muscles, pelvic wall)
  • NX - Regional lymph nodes (cannot be assessed)
  • N0 - No regional lymph node metastasis
  • N1 - Metastasis in regional lymph node or nodes

Regional lymph nodes are assessed via surgical removal or through biopsy of the pelvic lymph nodes, including the obturator chain. The surgical boundaries include the bifurcation of the common iliac, the obturator nerve, and the node of Cloquet.

Distant metastasis

Distant metastasis staging is as follows:

  • PM1c - More than 1 site of metastasis present
  • MX - Distant metastasis cannot be assessed
  • M0 - No distant metastasis
  • M1 - Distant metastasis
  • M1a - Nonregional lymph node(s)
  • M1b - Bone(s)
  • M1c - Other site(s)

Stage groupings

The TNM system for prostate cancer is based on the following five key pieces of information[7] :

  • The extent of the primary tumor (T category)
  • Whether the cancer has spread to nearby lymph nodes (N category)
  • The absence or presence of distant metastasis (M category)
  • The PSA level at the time of diagnosis
  • The Gleason score, based on prostate biopsy (or surgery)

Stage I - Cancer found in the prostate only:

  • T1, N0, M0, Gleason score 6 or less, PSA less than 10 or
  • T2a, N0, M0, Gleason score 6 or less, PSA less than 10

Stage II (IIa and IIb)- Cancer is more advanced than stage I, but has not spread outside the prostate:

Stage IIa - One of the following applies:

  • T1, N0, M0, Gleason score of 7, PSA less than 20 or
  • T1, N0, M0, Gleason score of 6 or less, PSA at least 10 but less than 20 or
  • T2a or T2b, N0, M0, Gleason score of 7 or less, PSA less than 20

Stage IIb - One of the following applies:

  • T2c, N0, M0, any Gleason score, any PSA or
  • T1 or T2, N0, M0, any Gleason score, PSA of 20 or more or
  • T1 or T2, N0, M0, Gleason score of 8 or higher, any PSA

Stage III - Cancer has spread outside the prostate and may have invaded the seminal vesicles:

  • T3, N0, M0, any Gleason score, any PSA

Stage IV - Cancer has spread outside the prostate, into surrounding pelvic organs, lymph nodes, or distant metastasis outside the pelvis:

  • T4, N0, M0, any Gleason score, any PSA or
  • Any T, N1, M0, any Gleason score, any PSA or
  • Any T, any N, M1, any Gleason score, any PSA

Risk classification

Guidelines from the European Society for Medical Oncology (ESMO) recommend classifying localized prostate cancer as follows, in order to guide prognosis and therapy[5] :

  • Low risk: T1–T2a and Gleason score ≤6 and PSA ≤10
  • Intermediate risk: T2b and/or Gleason score 7 and/or PSA 10-20
  • High risk: ≥T2c or Gleason score 8-10 or PSA >20

The ESMO recommends that patients with intermediate- or high-risk disease have nodal staging using CT, MRI, choline positron emission tomography/CT (PET/CT), or pelvic nodal dissection. Patients with intermediate- or high-risk disease should be staged for metastases using technetium bone scan and thoracoabdominal CT scan, whole-body MRI, or choline PET/CT.[5]

Previous
Next

Recent Advances: Molecular Markers

Currently, risk stratification for men who have recently been diagnosed with prostate cancer by biopsy is accomplished with the combination of prostate-specific antigen level, clinical stage, and Gleason score. The limitation of using these parameters for risk stratification is that collectively they do not address specific biologic features of prostate cancer, specifically the aggressiveness of tumor cells. In addition, many studies have shown that localized prostate malignancy can vary in potential for progression in different patients, despite similar risk-stratifying characteristics.

This problem has sparked the advent of research and use of biological/genomic assays to help risk stratify men diagnosed with localized prostate cancer. The theory behind utilizing genomic assays is to identify genes in biopsy specimens that potentiate cellular proliferation.

Cooperberg et al aimed to validate the application of the cell cycle progression score (CCP score) in identifying men at risk for recurrent disease after radical prostatectomy.[33] The CCP score identifies genes that promote cellular proliferation. In this study, the CCP score was compared with the Cancer of the Prostate Risk Assessment post-Surgical (CAPRA-S score), which risk stratifies recurrence after prostatectomy based on pre-procedural PSA, Gleason score, and clinical staging, and has been shown to have good accuracy.[33]

The CCP score predicted recurrence with a hazard ratio (HR) of 2.1 per unit increase in score.[33] In addition, the CCP score found an HR of 2.3 in some men with CAPRA-S scores of 0-2 (low risk of recurrence). Improved accuracy in predicting 10-year progression was noted when CCP score was combined with CAPRA-S score.[33]

In a similar study, Cuzick et al applied the CCP score to men with localized prostate cancer diagnosed by transurethral resection of the prostate (TURP).[34] The primary endpoint of the study was time to death. CCP score was found to be the most important variable and strongest prognostic factor for predicting time to death from prostate cancer.[34]

Klein et al assessed the use of Decipher, a 22-biomarker assay, on tissue retrieved from radical prostatectomy (RP) specimens from 1987 to 2008 for predicting the rate of recurrence. Within a cohort of 57 patients with preoperative diagnostic needle biopsy specimens, the primary objective was to validate biopsy-based Decipher for prediction of metastasis within 10 years of RP.[35] Biopsy-based Decipher was shown to be a significant predictor of recurrence within 10 years of RP, based on univariate and multivariate analysis, and was also a significant predictor of primary Gleason grade 4 or greater and rapid metastatic disease, two secondary endpoints of the study.[35]

In a review highlighting advantages and limitations of genomic testing, Falzarano et al note the vast variety of new testing available for aiding in diagnosis and risk stratification for prostate cancer.[36] In addition to the Prolaris/CCP score and Decipher, other genomic assays mentioned in the review include the following:

  • Confirm MDx
  • PCMT
  • Oncotype DX
  • Promark

Advantages of Confirm MDx and PCMT include a high negative predictive value (NPV), which reduces the need for repeat biopsies.[36] Limitations of Confirm MDx and PCMT are their inability to distinguish aggressive from indolent disease, which is a strength of the CCP score and Oncotype DX.[36] As described above, Decipher is unique in that it is a predictor of metastatic disease after RP.[36]

Previous
 
Contributor Information and Disclosures
Author

Lanna Cheuck, DO Director of Endourology, Montefiore Medical Center

Lanna Cheuck, DO is a member of the following medical societies: American Osteopathic Association, American Urological Association, Endourological Society, Society of Women in Urology

Disclosure: Nothing to disclose.

Coauthor(s)

Christopher S Atalla, DO Resident Physician, Department of Urology, Detroit Medical Center

Disclosure: Nothing to disclose.

Eric M Ghiraldi New York College of Osteopathic Medicine

Disclosure: Nothing to disclose.

Chief Editor

Edward David Kim, MD, FACS Professor of Surgery, Division of Urology, University of Tennessee Graduate School of Medicine; Consulting Staff, University of Tennessee Medical Center

Edward David Kim, MD, FACS is a member of the following medical societies: American College of Surgeons, Tennessee Medical Association, Sexual Medicine Society of North America, American Society for Reproductive Medicine, American Society of Andrology, American Urological Association

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Repros.

Acknowledgements

Tracey L Krupski, MD, MPH Assistant Professor, Department of Urology, University of Virginia School of Medicine

Tracey L Krupski, MD, MPH is a member of the following medical societies: American Medical Association, American Society of Clinical Oncology, American Urological Association, and Society of Women in Urology

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Reference Salary Employment

Dan Theodorescu, MD, PhD Paul A Bunn Professor of Cancer Research, Professor of Surgery and Pharmacology, Director, University of Colorado Comprehensive Cancer Center

Dan Theodorescu, MD, PhD is a member of the following medical societies: American Cancer Society, American College of Surgeons, American Urological Association, Medical Society of Virginia, Society for Basic Urologic Research, and Society of Urologic Oncology

Disclosure: Key Genomics Ownership interest Co-Founder-50% Stock Ownership; KromaTiD, Inc Stock Options Board membership

References
  1. [Guideline] Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010 Mar-Apr. 60 (2):70-98. [Medline].

  2. [Guideline] Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA Guideline. J Urol. 2013 Aug. 190(2):419-26. [Medline]. [Full Text].

  3. [Guideline] National Comprehensive Cancer Network. Prostate Cancer Early Detection Version 1.2016. NCCN. Available at http://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf. Accessed: March 1, 2016.

  4. [Guideline] US Preventive Services Task Force. Prostate cancer: Screening. Available at http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/prostate-cancer-screening. May 2012; Accessed: March 1, 2016.

  5. [Guideline] Parker C, Gillessen S, Heidenreich A, Horwich A, ESMO Guidelines Committee. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2015 Sep. 26 Suppl 5:v69-v77. [Medline]. [Full Text].

  6. Greene FL, Sobin LH. The TNM system: our language for cancer care. J Surg Oncol. 2002 Jul. 80(3):119-20. [Medline].

  7. How is prostate cancer staged?. American Cancer Society. Available at http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-staging. March 12, 2015; Accessed: March 1, 2016.

  8. Cancer Facts & Figures 2016. American Cancer Society. Available at http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf. Accessed: March 1, 2016.

  9. Daniels NA, Nielson CM, Hoffman AR, Bauer DC. Sex hormones and the risk of incident prostate cancer. Urology. 2010 Nov. 76(5):1034-40. [Medline]. [Full Text].

  10. Hoffman RM, Gilliland FD, Eley JW, Harlan LC, Stephenson RA, Stanford JL, et al. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2001 Mar 7. 93(5):388-95. [Medline].

  11. Lindquist KJ, Paris PL, Hoffmann TJ, Cardin NJ, Kazma R, Mefford JA, et al. Mutational landscape of aggressive prostate tumors in African American men. Cancer Res. 2016 Feb 26. [Medline].

  12. Hall IJ, Taylor YJ, Ross LE, et al. Discussions about prostate cancer screening between U.S. primary care physicians and their patients. J Gen Intern Med. 2011 Oct. 26(10):1098-104. [Medline].

  13. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002 Sep 12. 347(11):781-9. [Medline].

  14. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, el at. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009 Mar 26. 360(13):1310-9. [Medline]. [Full Text].

  15. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009 Mar 26. 360(13):1320-8. [Medline].

  16. Sandblom G, Varenhorst E, Rosell J, Löfman O, Carlsson P. Randomised prostate cancer screening trial: 20 year follow-up. BMJ. 2011 Mar 31. 342:d1539. [Medline]. [Full Text].

  17. Tang P, Sun L, Uhlman MA, Robertson CN, Polascik TJ, Albala DM. Prostate-specific antigen-based risk-adapted discontinuation of prostate cancer screening in elderly African American and Caucasian American men. Urology. 2010 Nov. 76(5):1058-62. [Medline].

  18. Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011 Dec 6. 155(11):762-71. [Medline].

  19. [Guideline] European Association of Urology. Guidelines on Prostate Cancer. Uroweb. Available at http://uroweb.org/wp-content/uploads/EAU-Guidelines-Prostate-Cancer-2015-v2.pdf. March 2015; Accessed: March 1, 2016.

  20. Lowry F. Test Spares Men Unnecessary Biopsies for Prostate Cancer. Medscape Medical News. Available at http://www.medscape.com/viewarticle/828845. July 24, 2014; Accessed: March 1, 2016.

  21. Bul M, van den Bergh RC, Rannikko A, Valdagni R, Pickles T, Bangma CH, et al. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program. Eur Urol. 2012 Feb. 61(2):370-7. [Medline].

  22. Bostwick DG, Qian J. High-grade prostatic intraepithelial neoplasia. Mod Pathol. 2004 Mar. 17(3):360-79. [Medline].

  23. Lee MC, Moussa AS, Yu C, Kattan MW, Magi-Galluzzi C, Jones JS. Multifocal high grade prostatic intraepithelial neoplasia is a risk factor for subsequent prostate cancer. J Urol. 2010 Nov. 184(5):1958-62. [Medline].

  24. Jung SI, Donati OF, Vargas HA, Goldman D, Hricak H, Akin O. Transition Zone Prostate Cancer: Incremental Value of Diffusion-weighted Endorectal MR Imaging in Tumor Detection and Assessment of Aggressiveness. Radiology. 2013 Nov. 269(2):493-503. [Medline].

  25. [Guideline] NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, Version 2.2016. National Comprehensive Cancer Network. Available at http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed: March 1, 2016.

  26. Choi WW, Williams SB, Gu X, Lipsitz SR, Nguyen PL, Hu JC. Overuse of imaging for staging low risk prostate cancer. J Urol. 2011 May. 185(5):1645-9. [Medline].

  27. Rastinehad AR, Turkbey B, Salami SS, Yaskiv O, George AK, Fakhoury M, et al. Improving detection of clinically significant prostate cancer: magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy. J Urol. 2014 Jun. 191 (6):1749-54. [Medline].

  28. Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015 Jan 27. 313 (4):390-7. [Medline].

  29. Sankineni S, George AK, Brown AM, Rais-Bahrami S, Wood BJ, Merino MJ, et al. Posterior subcapsular prostate cancer: identification with mpMRI and MRI/TRUS fusion-guided biopsy. Abdom Imaging. 2015 Oct. 40 (7):2557-65. [Medline].

  30. Bjurlin MA, Meng X, Le Nobin J, Wysock JS, Lepor H, Rosenkrantz AB, et al. Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment. J Urol. 2014 Sep. 192 (3):648-58. [Medline].

  31. Alberts AR, Schoots IG, Bokhorst LP, van Leenders GJ, Bangma CH, Roobol MJ. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans. Eur Urol. 2015 Dec 2. [Medline].

  32. Hu JC, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, et al. Targeted prostate biopsy in select men for active surveillance: do the Epstein criteria still apply?. J Urol. 2014 Aug. 192 (2):385-90. [Medline].

  33. Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol. 2013 Apr 10. 31 (11):1428-34. [Medline].

  34. Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011 Mar. 12 (3):245-55. [Medline].

  35. Klein EA, Haddad Z, Yousefi K, Lam LL, Wang Q, Choeurng V, et al. Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk. Urology. 2016 Jan 22. [Medline].

  36. Falzarano SM, Ferro M, Bollito E, Klein EA, Carrieri G, Magi-Galluzzi C. Novel biomarkers and genomic tests in prostate cancer: a critical analysis. Minerva Urol Nefrol. 2015 Sep. 67 (3):211-31. [Medline].

  37. Nanni C, Zanoni L, Pultrone C, Schiavina R, Brunocilla E, Lodi F, et al. 18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial. Eur J Nucl Med Mol Imaging. 2016 Mar 10. [Medline].

  38. Odewole OA, Tade FI, Nieh PT, Savir-Baruch B, Jani AB, Master VA, et al. Recurrent prostate cancer detection with anti-3-[18F]FACBC PET/CT: comparison with CT. Eur J Nucl Med Mol Imaging. 2016 Apr 18. [Medline].

 
Previous
Next
 
Estimated incidence of and mortality from prostate cancer. Courtesy of the American Cancer Society.
Relevant anatomy of the male pelvis and genitourinary tract.
Transrectal sonogram of the prostate showing a hypoechoic lesion in the peripheral zone of the gland that is suggestive of cancer.
Anterior and posterior bone scans of a patient with prostate cancer, with metastasis to the 12th rib and thoracic spine represented by the increased uptake of isotope.
Histologic scoring system (the Gleason scoring system) showing the 2 most common patterns seen on biopsy specimens in prostate cancer.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.